3SBio Reports Long-Term Tivunatamig Plus Chemo Data in First-Line Advanced NSCLC
Start here
At ESMO 2026, 3SBio presented long-term follow-up results from a China Phase II study of tivunatamig (SSGJ-707) combined with chemotherapy as first-line treatment for advanced non-small cell lung cancer. The regimen showed median progression-free survival of 13.6 months in patients with squamous disease and 13.8 months in those with non-squamous disease. The data come from a Phase II trial conducted in China; the findings now stand as the current evidence base for the combination in this setting. Longer-term outcomes and confirmation in larger trials remain to be established through further study.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPick2026 ESMO: 3SBio Reports Long-Term Follow-up of Tivunatamig Plus Chemo in First-Line Advanced NSCLC China Phase II
3SBio presented long-term follow-up data at ESMO 2026 for tivunatamig (SSGJ-707) plus chemotherapy as first-line treatment of advanced NSCLC in a China Phase II study. Median PFS was 13.6 months in squamous and 13.8 months in non-squamous disease.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 28 18:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.